Category Regional Policy

The 2011 Drug Patent ‘Cliff’ And The Evolution Of IP Valuation

In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how to recognise the true value of a firm’s intellectual property. Companies are realising that simply accumulating patents does not necessarily increase their firms’ value, but it is how those patents are used that can attract capital. And drug companies facing massive numbers of upcoming patent expiries, a deflated economy and other market pressures, are looking to diversify their portfolios to stay in the black.

Patent On AIDS Medicine Denied In India; Seen Unlocking Market

A decision by the Indian Patent Office to reject a patent on an AIDS drug last week has drawn acclaim from civil society and Indian generic pharmaceutical industries. The decision was not based on a controversial article of Indian law aimed at preventing patent extensions but rather on the grounds of non-inventiveness. Abbott Laboratories, meanwhile, presented Intellectual Property Watch with justification for its Indian patent request.

What If There Were An Application For Dot Wikileaks?

What would happen if the Internet Corporation for Assigned Names and Numbers (ICANN) received an application for a .wikileaks top level domain name (TLD) next year, under its new system of opening up the internet for domains? It could make an interesting example of how well the complex system to apply for new TLDs works and how much political intervention is possible in the system. At the 39th ICANN meeting in Cartagena, Colombia this week, the self-regulatory body is trying to finalise issues in the published Final Applicant Guidebook - and it is governments and trademark owners that are calling for more time and more procedures.